Invero Pharma is a late clinical-stage pharmaceutical company developing xenon to protect against brain cell death, and potentially other organ damage, following acute neurologic injury. Our initial product is XENEX® (xenon) gas for inhalation in combination with temperature management for Post Cardiac Arrest Syndrome (PCAS) patients.
Invero Pharma
info@inveropharma.com